:: allon therapeutics
August 13, 2011

View all of Allon Therapeutics's Presentations. Industry Medical / Health Care; About Allon Therapeutics Inc. is a clinical-stage biotechnology company

August 29, 2011

Allon Therapeutics Inc company profile in Vancouver, Canada. Our company profile report for Allon Therapeutics Inc includes business information such as

Allon Therapeutics Inc. 1681 Chestnut St # 315, Vancouver, British Columbia, V6J 4M6. Phone: 604-736-1616. Categories: Laboratories-research &

Global Markets Direct,2011년 11월 발행 「Allon Therapeutics Inc. : 제품 파이프 라인 리뷰」

CHICAGO, ILLINOIS--(Marketwire - July 30, 2008) - Allon Therapeutics Inc.

May 4, 2012

VANCOUVER, BRITISH COLUMBIA -- (Marketwire) -- 10/20/11 -- Allon Therapeutics Inc. (TSX: NPC) announced today that it has successfully

Aegerion Pharmaceuticals, Inc Aeolus Pharmaceuticals, Inc. Affimed Therapeutics AG Afraxis, Inc. Akebia Therapeutics, Inc Allon Therapeutics Inc. Allozyne Inc.

Jun 16, 2008 - Nextrials, Inc., a leader in clinical research software and services, today announced that its flagship Prism(R) clinical trial

From Yahoo! Finance: VANCOUVER, BRITISH COLUMBIA-- -

October 31, 2011

Allon Therapeutics Inc. is a Canadian biotechnology company developing drugs that protect against neurodegenerative conditions such as

Allon Therapeutics Inc.-Therapeutic Competitors Report, published March 2011, pages 57, Allon Therapeutics Inc.-Therapeutic Competitors Report Report

Allon Therapeutics Inc. is a clinical stage biotechnology company focused o More To interact with Allon Therapeutics you need to sign up for Facebook first.

ALLON THERAPEUTICS INC (NPC:CN) stock price & investing information. Find ALLON THERAPEUTICS INC historical stock quotes, key competitors, stock

May 10, 2012

Dr. Illana Gozes is Chief Scientific Officer, Director of Allon Therapeutics Inc. She has Dr. Gozes is a founder of Allon Therapeutics and Professor of Clinical

Allon Therapeutics Inc. (TSX: NPC) announced today that it has initiated a pivotal Phase 2/3 clinical trial to evaluate the Company's lead

Allon Therapeutics Inc.-Company Report provides up to date insight into the structure and operations of privately-held pharmaceutical,

Allon Therapeutics Inc. (TSX: NPC) yesterday announced that the Phase IIa clinical trial of its lead candidate davunetide achieved measurable

September 22, 2011

Allon Therapeutics, Inc. company research & investing information. Find executives and the latest company news.

VANCOUVER, BRITISH COLUMBIA — (Marketwire) — 06/06/11 — Allon Therapeutics Inc. (TSX: NPC) today announced it will receive the

VANCOUVER, BRITISH COLUMBIA -- (Marketwire) -- 05/11/10 -- Allon Therapeutics Inc. (TSX: NPC) today announced publication of data from

Dr Gozes is President of the Israel Society for Neuroscience (ISFN), the Scientific Founder and Chief Scientific Officer of Allon Therapeutics Inc. and the

April 12, 2012

Allon Therapeutics Releases Q3 Operating Results and Provides Corporate Allon Therapeutics Announces Completion of Patient Enrollment in Pivotal Trial

Allon Therapeutics Inc. - Company Report provides up to date insight into the structure and operations of privately - held pharmaceutical,

B2B - Directory · Register Your company · Contract Manufacturing · Contract Research · Companies by Sector · Drugs by Therapeutic Area · Advertisement

Download Historical Stock Quotes for Allon Therapeutics Inc. [TSX,NPC] in a range of formats.

August 20, 2011

The drug is in clinical development by Vancouver based Allon Therapeutics for Alzheimer's disease and other neurodegenerative disorders.

Business: Allon Therapeutics Inc, Address: 1681 Chestnut St # 315, City: Vancouver, Province: British Columbia, Phone: 604-736-1616.

Navigation Options ----, -Allon Therapeutics Inc. -, Company News and Bulletins, Directors and *NPC, *Allon Therapeutics Inc. TSX Venture, DELIST

The Institute for the Study of Aging (ISOA) has invested in Allon Therapeutics, a start-up biotechnology company. Allon Therapeuti.

May 5, 2012

VANCOUVER, BRITISH COLUMBIA--(Marketwire - June 2, 2011) -Allon Therapeutics Inc. (TSX:NPC) today announced its unaudited operating

Allon Therapeutics, a biotechnology company, has announced preclinical data demonstrating the potential of AL-309, the company's

Allon Therapeutics Inc operates in the Biological products exc. diagnostic sector. Allon Therapeutics Inc. (Allon) is a clinical-stage biotechnology company

Allon Therapeutics Announces Completion of Patient Enrollment in Pivotal Trial Gordon McCauley, Allon's President and CEO, said the Company expects to

December 13, 2011

Allon Therapeutics Inc (Other OTC Issues : NPCUF). Trade now · Add to Watchlist · Get chart · Print report. Find prices for: 0.23 unch Delayed. MORE ABOUT

Allon Therapeutics Inc., a clinical-stage biotechnology company, has appointed Michael Gold as vice president of clinical development and

VANCOUVER — Allon Therapeutics Inc. (TSX: NPC) announced today it has entered into a standby equity distribution agreement (SEDA) with

Allon Therapeutics Inc. - Product Pipeline Review - Q4 2010. Nov 2010 - 40 pages - $500. Allon Therapeutics Inc.-Therapeutic Competitors Report. Nov 2010

March 19, 2012

Allon Therapeutics Inc. is a clinical-stage biotechnology company focused on bringing to market innovative central nervous system therapies. Allon's lead drug

Company Description: Allon Therapeutics Inc. is a clinical-stage biotechnology company developing treatments for neurodegenerative conditions. Its davunetide

Allon Therapeutics Inc. is a Canadian biotechnology company developing drugs that protect against neurodegenerative conditions such as Alzheimer's disease,

Add to. BTV Weekly Market Wrap: Oct 21by BusinessTelevision68 views · Thumbnail 1:01. Add to VantageClips Featuring Allon Therapeuticsby

February 24, 2012

Allon Therapeutics, a British Columbia-based clinical-stage biotechnology company that develops first drugs to combat the progression of

Message Boards Settings Allon Therapeutics, Inc. Search : in. Allon Therapeutics , Inc. board, Stocks A category, Stocks (A to Z) category, All Yahoo! Message

VANCOUVER, B.C. — Allon Therapeutics Inc. today issued an update on the progress of the pivotal Phase 2/3 clinical trial that is evaluating

Allon Therapeutics, Inc. Company & Business Contact information- Jigsaw Business Directory. Get complete contact & company information with emails and

February 1, 2012

Allon Therapeutics Inc. (Toronto:NPC) Contact Information Allon Therapeutics Inc . 506-1168 Hamilton St.

Allon Therapeutics Inc, 1168 Hamilton Street, Vancouver BC V6B 2S2, 604-736- 0634.

Vancouver-based biotech company Allon Therapeutics (TSX: NPC) said that it recieved $500000 in US government grants for its davunetide

Allon Therapeutics Wins National Biotech Award [June 6, 2011 - 05:31 AM PST]: Jun. 6, 2011 (Marketwire Canada) -- VANCOUVER, BRITISH

January 1, 2012

Symbol: NPC:CA, Name: Allon Therapeutics Inc., Title: Allon Therapeutics Inc. ( NPC:CA) Stock Quote.

Allon Therapeutics, Inc. Closes $2.5 Million Investment to Advance Clinical Development from Market Wire.

Allon Therapeutics Wins National Biotech Award from Market Wire.

Allon Therapeutics Vancouver. Allon Therapeutics. Visit Website · Print · Email Friend · Download PDF · Report Listing · Bookmark and Share. Allon

September 28, 2011

Allon Therapeutics Inc., an early stage biotech company, engaged Epic PR to raise awareness of its company and neurodegenerative drugs with potential

Allon Therapeutics IncTSX/Alpha:NPCview on OTC Markets Group Inc - Grey Market » · Help. Symbol Lookup. No Matches were found for. Additional matches

Allon Therapeutics Closes $20 Million Bought Deal Offering.

Comparison of Allon Therapeutics, Inc. and Direct Competitors Financial Ratios. 5.3. Allon Therapeutics, Inc. Cash Flow Statement Key Figures. Table 7.

December 23, 2011

Allon Therapeutics has announced its completion of the enrollment objective of 300 patients in the phase 2/3 pivotal clinical trial evaluating the

Gordon McCauley of Allon Therapeutics Inc. with the award for Allon Therapeutics Inc. is focused on bringing to market innovative central nervous system

View performance charts for Allon Therapeutics Inc (). View Allon Therapeutics Inc share price charts. Hargreaves Lansdown gives you free access to research,

Contributing to the day's overall success were investors of Allon Therapeutics Inc. (TSX:NPC), who experienced a 6.87% up-tick accompanied

March 4, 2012

Company invites investors and analysts to log-on to March 3rd CEO presentationVANCOUVER, British Columbia, March 7, 2011 /PRNewswire/

NPC Allon Therapeutics Inc. Allon Therapeutics Wins National Biotech Award.

Allon Therapeutics Inc. : Stock quote, stock chart, quotes, analysis, advice, financials and news for share Allon Therapeutics Inc. | Nasdaq other OTC: NPC

Allon Therapeutics Inc. company information, data and profile. Benchmark the business against its key industry competitors.

September 5, 2011

VANCOUVER, BRITISH COLUMBIA--(Marketwire - Oct. 20, 2011) - Allon Therapeutics Inc. (TSX: NPC) announced today that it has

Allon Therapeutics Inc. (TSX:NPC) announced today that it has been granted a United States patent covering the use of Allon's drug candidates

Allon Therapeutics Inc. is a clinical-stage biotechnology company focused on developing the first drugs that impact the progression of neurodegernative

Sorry! Could not find what you're looking for. What are you looking for? Search the News. RSS PILLSCRIBE ON TWITTER · pillscribe: Indian biotech revenues

September 13, 2011

TradingMarkets | Allon Therapeutics Inc., a clinical-stage biotechnology company , has appointed Michael Gold as vice president of clinical

Get real-time stock quote for Allon Therapeutics Inc. NPCUF including chart, current price, historical price, news, financial statements, balance sheet, income

Fasken Martineau is mentioned on TechFinance as legal counsel to GMP Securities L.P. in the matter of Allon Therapeutics' unit offering

Allon Therapeutics Inc at 1168 Hamilton St, Vancouver, BC V6B 2S2.

October 30, 2011

Product profiles for late stage and clinical stage products of Allon Therapeutics Inc. with complete description of the product's developmental

Thursday May 11, 8:30 am ET VANCOUVER, BRITISH COLUMBIA--( CCNMatthews - May 11, 2006) - Allon Therapeutics Inc. (TSX:NPC

Financial Post Allon Therapeutics Inc. Allon Therapeutics Inc. Canada's most disappointing tech stocks. While some Canadian technology stocks are climbing

Meanwhile, Xconomy profiled the Vancouver, Canada-based Allon Therapeutics, which believes its peptide davunetide is the most advanced

February 19, 2012

Allon Therapeutics, 506-1168 Hamilton Street, Vancouver, BC, V6B 2S2, Canada . new therapeutic developments in the field of neurodegenerative diseases.

Allon Therapeutics - Allon Therapeutics Inc. is a clinical stage biotechnology company focused on commercializing high potential central nervous system drugs.

Vancouver, BC, December 8, 2011--Allon Therapeutics today announced that its shareholders have approved the investment by Neuro Discovery II Limited

VANCOUVER, BRITISH COLUMBIA -- (Marketwire) -- 11/30/11 -- Allon Therapeutics Inc. (TSX:NPC) announced today that it has been granted a United States

October 19, 2011

AL-108 is being developed by Allon Therapeutics (TSX: NPC), a Canadian biotechnology company located in Vancouver. The drug was

Allon Therapeutics Inc Allon Logo Allon Therapeutics Inc. is a clinical stage

CANADA - Neuro Discovery Inc (ND) acquired all the outstanding stock of Allon Therapeutics Inc, a biopharmaceutical company, in exchange for #.### mil ND

Allon Therapeuticsby AllonTherapeutics 275 views · Thumbnail 1:01. Add to VantageClips - American Creek Resources Ltd.by VantageClips

August 22, 2011

HL:Allon Therapeutics fiscal 2009 net loss cut to $7.3 million from $11.3 million@

VANCOUVER, BRITISH COLUMBIA-- - Allon Therapeutics Inc. announced today it has closed a financing agreement with Isar Pharma K/S , a

Allon Therapeutics Inc. Director, Investor Relations (604) 742-2540 or Cell: . TradingMarkets News for NPC,NPCUF - Allon Therapeutics AL-108 Human

Allon Therapeutics Inc. is a clinical-stage biotechnology company focused on developing the first drugs that impact the progression of neurodegenerative

October 29, 2011

Find Research Analysis On Allon Therapeutics Inc. NPCUF Including Analyst Reports and Sector Reports.

Get the latest NPC stock information on the web. Get the latest stock quote and more - DailyFinance is your source for ALLON THERAPEUTICS

Allon Therapeutics Inc. (TSX: NPC) announced today that it has received a major grant from the Michael J. Fox Foundation for Parkinson's

Allon Therapeutics Inc. (Allon) is a clinical-stage biotechnology company developing treatments for neurodegenerative conditions. Allon's drug

March 8, 2012

Allon Therapeutics, a biotechnology company based in Vancouver, British Columbia, has named Dr. Michael Gold vice president of clinical

Allon Therapeutics Inc. (TSX: NPC) announced today that it has successfully achieved the enrollment objective of 300 patients in the phase 2/3

Allon Therapeutics, Alzheimer's disease, Prof. Illana Gozes, _x0000_i1030. Allon Therapeutics, MCI/stroke, Prof. Allon Therapeutics, Schizophrenia, Prof.

AIM Therapeutics Inc. Canada, Visit their website. Algiax Pharmaceuticals GmbH, Germany. Allon Therapeutics (Toronto Stock Exchange (TSX):NPC), Canada

February 18, 2012

Allon's Intellectual Property Portfolio Strengthened With Additional U.S. Patent 11 /30/2011 8:30:08 AM - Market Wire Canada. Allon Therapeutics Releases Q3

US:NPCUF - Get Stock quote detail for Allon Therapeutics Inc. Stock quotes include the latest US:NPCUF market price and fundamental investing data, price.

Comprehensive Real-Time News Feed for Allon Therapeutics.

Allon Therapeutics Inc. announced today commencement of a pilot clinical trial in the Company's program to develop its lead neuroprotective

April 23, 2012

Allon Therapeutics Inc. (TSX: NPC) CEO Interview. Posted by admin - 28/07/10 at 08:07 pm. This interview has expired. Click here to find stocks, with exciting

Allon Therapeutics Inc. (TSX:NPC) is a Canadian biotechnology company developing drugs that protect against neurodegenerative conditions

Biotechnology start-up Allon Therapeutics has announced a $2.5 million financing round. Founded in 2002, the company has raised $250000

Significant reduction in levels of beta-amyloid and phosphorylated tau Significant behavioral outcome in animals. Allon Therapeutics Inc.

August 13, 2011

Allon Therapeutics Inc. is a clinical-stage biotechnology company developing treatments for major neurodegenerative conditions. Allon has 3 Phase II human

Joined hundreds of Canada's life sciences leaders to applaud Cardiome Pharma Corp., Allon Therapeutics and EnWave Corp., as the firms'

11.12.2011 15:00:30 - Fast Market Research recommends "Allon Therapeutics Inc. - Product Pipeline Review - H2 2011" from Global Markets Direct, now

Allon Therapeutics Inc. (TSX: NPC), a clinical-stage biotechnology company focused on bringing to market innovative central nervous system

March 10, 2012

Allon Therapeutics Inc. today announced its unaudited operating results for the three months More Allon Therapeutics News from Topix »

Discover the latest info about npc to summary for allon therapeutics inc yahoo finance and read our other article related to npc to summary for

Allon Therapeutics Inc. ©2010 Allon Therapeutics Inc. 1 . ©2010 Allon Therapeutics Inc. 12. Davunetide: Allon's approach to a tau-therapeutic

Allon Therapeutics Inc. announced it received the Gold Leaf Award as the Early Stage Company of the Year from BIOTECanada, Canada's

October 29, 2011

Allon Therapeutics Inc. Product Pipeline Review H2 2011 Summary Global Market Direct s pharmaceuticals report, Allon Therapeutics Inc. - Product

Allon Therapeutics to list shares on the Toronto Stock Exchange. - Find CNW Group articles.

Allon Therapeutics Inc. is a clinical-stage biotechnology company developing treatments for neurodegenerative conditions. Allon's drug, davunetide, has

Download Allon Therapeutics Q1 2011 Report pdf documents from

February 18, 2012

Company profile for Allon Therapeutics. Includes latest key event, news and commentary, top selling products, worldwide prescription sales, sales by therapy

Allon Therapeutics Share Price (NPC) Share Prices, Charts, News, Financials, and More - Digital Look.

Allon Therapeutics Inc. (TSX: NPC) has announced the preclinical data which demonstrates the potential of AL-309. AL-309.

Allon Therapeutics' AL-208 product successful in Phase I clinical trial.

March 20, 2012

©2011 Allon Therapeutics Inc. 2. Statements Allon may eventually develop. Other risk factors These factors can be reviewed in Allon's public filings at www .

Welcome to the company profile of Allon Therapeutics on LinkedIn. Allon Therapeutics Inc. is a clinical-stage biotechnology company focused on bringing to

Vancouver-based biotech company Allon Therapeutics Inc. has been awarded US$500000 in grants from the U.S. government to fund

Home | Login | Stockstream. Allon Therapeutics Inc. npc go to snapshot add to favorites. post next page. see all posts, Overall Quality 2+, Overall Quality 3+

May 18, 2012

Company profile for Allon Therapeutics Inc. in Vancouver,BC. Get accurate business information including key contacts, company financials and more in the

Allon Therapeutics Inc. is a clinical-stage biotechnology company developing treatments for major neurodegenerative conditions. In Q1 2008, Allon's drug

EV / Revenue Use Average, NPC Allon Therapeutics Inc. DNA Genentech, Inc. Change, AMGN Amgen, Inc. Change, GILD Gilead Sciences, Inc. Change, CELG

Company invites investors and analysts to attend interactive real-time virtual conferenceVANCOUVER, British Columbia, Feb. 28, 2011

February 1, 2012

Allon Therapeutics Releases First Quarter Operating Results.

VANCOUVER, BRITISH COLUMBIA-- - Allon Therapeutics Inc. announced today that its lead neuroprotective drug candidate, davunetide, has

26, 2010) - Allon Therapeutics Inc. (TSX:NPC) a nounced today commencement of a pilot clinical trial in the Company's program to develop its.

Sign up for Twitter to follow Allon Therapeutics (@AllonT). The official Twitter site of Allon Therapeutics, Inc.

December 17, 2011

Allon Therapeutics Inc. (NPC.TO) provided an update on progress in its pivotal clinical trial in progressive supranuclear palsy or PSP and

This notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i), announces that the National Institutes of Health, Department of

Allon Therapeutics Inc. (TSX:NPC) ("Allon Therapeutics" or the "Company") Prior to the Offering, Allon Therapeutics had 78.8 million common

Allon Therapeutics Announces Publication of davunetide Data Demonstrating Cognition Improvement in Schizophrenia Model.

October 29, 2011

Allon Therapeutics Inc. 506-1168 Hamilton Street VANCOUVER BC V6B 2S2 CANADA More information. Phone : 1 604 736 0634. Fax : 1 604 736 1616

VANCOUVER, British Columbia, Feb. 28, 2011 /PRNewswire/ -- Allon Therapeutics Inc. , today announced that Gordon C. McCauley, President

Allon Therapeutics Inc - Vancouver - phone number & address - BC - Research & Development Bureaus.

Allon Therapeutics' presentation will be available 24/7 for 90 days. Investors may download shareholder materials from the "virtual trade booth" for the next three

February 16, 2012

Allon Therapeutics Inc. - Product Pipeline Review - Q4 2010 provides data on the company's research and development focus. The report

ALLON THERAPEUTICS INC. is a clinical stage biotechnology company developing drugs that protect agai.

Allon Therapeutics. Alistair Stewart, PhD. 22 Jun 2009 Bruce H Morimoto. 04 Jun 2009 Syndicate content. Latest News. Merck dumps Parkinson's program

Allon Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of drugs to treat neurodegenerative diseases. Its lead product,

December 9, 2011

News and bulletins about Allon Therapeutics for biotechnology, life sciences, pharmacy, healthcare, diagnostics, bioinformatics, updated daily and relevant to

Facts and figures about Allon Therapeutics Inc., taken from Freebase, the world's database.

Rick Smith Jr is the Director, Investor Relations Communications of Allon Therapeutics. Details from Lead411 could include email - @allontherapeutics. com,

Apr 3, 2007 - Allon Therapeutics Inc. (TSX NPC), The Neuro Protection Company (TM), announced today the publication of new preclinical data from additional

January 14, 2012

Find financial news for Allon Therapeutics Inc. (TSE:NPC) using Google Finance.

2 Allon Therapeutics, Inc. Interview Questions, Click Next for Next Interview Question. Question #2: Tell me about a time you have failed at a project in your life.

Allon Therapeutics Aktie im Überblick: Kurs, Realtimekurs und Chart. Nachrichten und Diskussionen zu Allon Therapeutics (CA0197741089, NPC, A0DP1L)

The Allon Therapeutics Inc. (NPCUF) Company Profile report lists Allon of key business relationships for Allon Therapeutics Inc. are all available at the click of

November 22, 2011

Allon Therapeutics Inc. NPCUF (OTN). AD: Find a Broker; Help. Real-time prices for U.S.-listed stocks, including premarket and after hours, reflect trading

VANCOUVER, BRITISH COLUMBIA -- (Marketwire) -- 10/20/11 -- Allon Therapeutics Inc. (TSX:NPC) announced today that it has successfully

Allon Therapeutics Inc. (Allon) is a clinical-stage biotechnology company developing treatments for neurodegenerative conditions. Allon's drug, davunetide, is

Pharmacy Choice - Pharmaceutical News - Allon Therapeutics Releases Q3 Operating Results and Provides Corporate Update - December 17

January 28, 2012

Allon Therapeutics Provides Pivotal Study Update and Q2 Operating Results [ August 12, 2011 - 14:00 PM PST]: VANCOUVER, BRITISH

Allon's detailed financials; Comprehensive pipeline breakdown, including molecular targets & partnerships. 17 years of in-depth BioPharma industry analysis.

Allon Therapeutics Inc. (TSX: NPC) is developing drugs that target neurodegenerative diseases like dementia, schizophrenia and Parkinson's

Tag Archives: Allon Therapeutics the application by Merus to graduate to the TSXV, and the filing by Allon Therapeutics of a short-form preliminary prospectus.

December 26, 2011

Allon Therapeutics Inc. (Allon) is a clinical-stage biotechnology company developing treatments for neurodegenerative conditions. Allon's drug, davunetide, has

Allon Therapeutics. Clinical Phase II. Merz Pharmaceuticals. Pre-Clinical. Neurophage Pharmaceuticals. Pre-Clinical. NasVax. Pre-Clinical. Allon Therapeutics

VANCOUVER, BRITISH COLUMBIA--(Marketwire - Sept. 14, 2011) - THIS PRESS RELEASE IS NOT FOR DISSEMINATION IN THE UNITED

Health care industry insiders provide analysis & data on pharma biotech device & diagnostic company strategy & trends. Deals & technology

January 27, 2012

Allon Therapeutics Inc. (TSX: NPC) yesterday announced that the Phase Iia clinical trial of its lead candidate davunetide achieved measurable

Subscriptions. Get emailed when Allon Therapeutics Inc. is picked. Subscribe. Pricing & Charts. Lookup NPC.TO at Yahoo Finance · Feedback

Hoovers company profile of Allon Therapeutics Inc.. Find detailed business information such as key executives, financials and other corporate data on Allon

Allon Therapeutics Inc. Announces New Findings Of Davunetide Allon Therapeutics Inc. announced new findings that 12 weeks of treatment

January 29, 2012

VANCOUVER, BRITISH COLUMBIA-- - Allon Therapeutics Inc. today released top-line results from an imaging study of schizophrenia patients

Allon Therapeutics Inc specializes in Laboratories-Research & Development and is located in Vancouver BC.

For the three months ended March 31, 2010, research and development expenses were $2167911 compared to $1198936 for the same

Stock quote, stock chart, quotes, analysis, advice, financials and news for share ALLON THERAPEUTICS | Nasdaq other OTC: NPC | Nasdaq other OTC.

October 30, 2011

Allon Therapeutic Inc. (NPCUF.PK) shares jumped more than 40% yesterday. On Tuesday, the company said that a clinical trial of its drug

Preclinical research with Allon Therapeutics intranasal davunetide shows improved motor function in Parkinson's Disease model.

Allon Therapeutics Inc. announces its 2009 milestones and confirmed that the company's existing cash resources are sufficient to fund its business into 2011.

VANCOUVER, BRITISH COLUMBIA, Sep 22, 2011 (Marketwire via COMTEX News Network) -

December 6, 2011

H2 2011” provides data on the Allon Therapeutics Inc.'s research and Allon Therapeutics Completes Private Placement Of Common Shares For $3 Million

Marketwire VANCOUVER, BRITISH COLUMBIA--(Marketwire - Feb. 5, 2010) - Allon herapeutics Inc. (TSX:NPC) President and CEO Gordon

Allon Therapeutics news and press releases about recent investments, fund and portfolio company news, new hires and events.

Allon Therapeutics, Inc., (NPC) announced that the company's proprietary compound NAP has been shown in preclinical studies to be effective

January 4, 2012

Stock analysis for NPC:CN. Get stock price, historical stock charts & news for Allon Therapeutics Inc, in the Therapeutics industry.

Allon Therapeutics, Inc. Announces Presentation of Davunetide Data During 10th International Conference on Alzheimer's and Parkinson's Disease 3/11/2011

Allon Therapeutics Inc. 506-1168 Hamilton St Vancouver, BC V6B 2S2 Tel: (604) 736-0634. Fax: (604) 736-1616. Contact Name Rick Smith. Industry 35201010

Find out the latest news headlines for ALLON THERAPEUTICS INC. (NPC.TO).

September 26, 2011

Free Allon Therapeutics Stock charts (TSE:NPC). Historical, Intraday and Live Allon Therapeutics charts with more than 80 charting studies and tools.

Allon Therapeutics enrolls for frontal dementia trial | CenterWatch News Online.

Preliminary animal and Phase II human trials have shown that Davunetide, a creation of Allon Therapeutics, Inc., has potential as a treatment

Allon Therapeutics Inc. Allon Therapeutics Inc. CEO Clips | June 21, 2010 Watch more videos from CEO Clips. Tags:. .allon. .therapeutics

December 14, 2011

July 09, 2008 - Allon Therapeutics Inc. (TSX: NPC), announced that it has been granted a United States patent covering composition, delivery

Today we will analyze the stock ALLON THERAPEUTICS INC (NPC.TO) for internet stock trading in the TO stock market, Stock Technical

Allon Therapeutics earnings per share revisions and analysts forecast | Toronto Stock Exchange: | Toronto Stock Exchange.

Allon Therapeutics. Gordon McCauley, CEO of Allon Therapeutics (a publicly traded bio-tech company) speaks about his company's recent successes.

September 30, 2011

Renewable Energy Financial News, Stocks, Companies, and Market Research.

On July 15, 2008, Allon Therapeutics Inc. (TSX:NPC), announced that it had completed its previously annonced bought deal public offering of common shares .

Allon Therapeutics to Present New Data at Leerink Swann Alzheimers Conference. - Business Wire - April 03, 2007 - April 03, 2007

Send an email message to ALLON THERAPEUTICS INC. ALLON THERAPEUTICS INC is a Pharmaceutical Preparation Manufacturing company located in

October 17, 2011

Allon Therapeutics Inc. reported today in its Second Quarter 2008 operating results that the Company achieved all its clinical and financial

Allon Therapeutics Inc. (NPC) - Financial and Strategic SWOT Analysis Review - new company profile published Allon Therapeutics Inc. (NPC)

Allon Therapeutics Announces Completion of Patient Enrollment in Pivotal Allon has obtained Orphan Drug and Fast Track Status in the U.S.

Stock analysis for NPCUF:US. Get stock price, historical stock charts & news for Allon Therapeutics Inc, in the Therapeutics industry.

April 13, 2012

Allon Therapeutics Appoints Steven Whitaker CMO.

Allon Therapeutics Inc. is a clinical-stage biotechnology company focused Allon Therapeutics Releases Q3 Operating Results and Provides

2, 2011) - Allon Therapeutics Inc. (TSX:NPC) announced today that a research project funded by the Michael J. Fox Foundation (MJFF) for

Allon Therapeutics Inc: Business description, financial summary, 3yr and interim Allon Therapeutics Inc. announced that it has completed the previously

November 28, 2011

NPCUF Allon Therapeutics Inc - Detailed financial news for NPCUF Allon Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the

Allon Therapeutics Inc See also: Detailed Chart | Financials | Filings.

Allon Therapeutics Inc. ©2008 Allon Therapeutics obtaining regulatory approval to market any product which Allon may eventually develop. Other risk factors

AL-108 is being tested on Alzheimer's first, but they plan to try it for MS too, so I figure these Phase I safety studies won't have to be done all

January 31, 2012

Allon Therapeutics' lead drug to be fast tracked in U.S..

Summary financial information on Allon Therapeutics Inc.

Allon Therapeutics Wins National Biotech Award VANCOUVER, BRITISH COLUMBIA -- (Marketwire) -- 06/06/11 -- Allon Therapeutics Inc. (TSX: NPC) today

Illana Gozes, PhD, Allon Therapeutics Inc. 9:35ñ9:55. The Discovery and Preclinical Progress of the Neuroprotective Peptide, davunetide, in the Treatment of

March 28, 2012

Find financial news for Allon Therapeutics Inc. (TSE:NPC) using

Allon Therapeutics Inc.-Company Report. Allon Therapeutics Inc.-Company Report provides up to date insight into the structure and operations of

Allon Therapeutics Inc ★ , Vancouver, 6047361616.

VANCOUVER, B.C. - Allon Therapeutics Inc. announced that it has successfully achieved the enrollment objective of 300 patients in the phase

April 15, 2012

Information provided by (Responsible Party): Allon Therapeutics Further study details as provided by Allon Therapeutics: Primary Outcome

VANCOUVER, BRITISH COLUMBIA, Apr 06, 2010 (MARKETWIRE via COMTEX) --Allon Therapeutics Inc. /quotes/comstock/11t!e:npc (CA:NPC

Allon Therapeutics Inc. announced the appointment of Gordon C. McCauley to its Board of Directors. McCauley is President and Chief

Allon Therapeutics is involved in the discovery, development and commercialization of drugs to treat neurodegenerative diseases that lead to memory loss and

September 6, 2011

ALLON THERAPEUTICS INC (NPC:CN) stock price & investing information. Find ALLON THERAPEUTICS INC historical stock quotes, key

Everything relating to Allon Therapeutics: compilations of facts, news, background knowledge, product information and market trends can be found here in the

Allon Therapeutics Inc. (TSX:NPC) is a Vancouver-based biotechnology company developing drugs that protect against neurodegenerative conditions such as

Allon Therapeutics Inc. (TSX: NPC) today announced it will receive the Gold Leaf Award as the Early Stage Company of the Year (Health) from

April 21, 2012

Allon Therapeutics Provides Pivotal Study Update and Q2 Operating Results.

Allon Therapeutics Inc. (TSX: NPC) announced that it has been granted a United States patent covering the use of Allon's drug candidates,

Gordon McCauley, CEO of Vancouver's Allon Therapeutics receives the BIOTECanada Gold Leaf Award for 2011 Early Stage Company of the

Completed: On October 18, 2011, Allon Therapeutics completed public offering of 9767500 units at a price of CAD0.25 ($0.25) per unit,

January 20, 2012

Allon Therapeutics Inc Allon Logo A STRONG FOUNDATION Find out why Allon's clinical development strategy identifies opportunities. UPDATE FROM CEO

Please note: More presenting companies to come, please

Results 1 - 10 of 59 Allon Therapeutics Inc. is a clinical-stage biotechnology company focused on bringing to market innovative central nervous system therapies.

VANCOUVER, BRITISH COLUMBIA--(Marketwire - Oct. 18, 2011) - Allon Therapeutics Inc. (TSX:NPC) - THIS NEWS RELEASE IS INTENDED

March 3, 2012

Allon Therapeutics, Inc. develops drugs that protect against euro degenerative conditions such as Alzheimer's disease, mild cognitive impairment, traumatic

ALLON THERAPEUTICS INC (NPCUF:US) stock price & investing information. Find ALLON THERAPEUTICS INC historical stock quotes, key

Allon Therapeutics Inc announced today that the results of the completed Phase Ib clinical trial of a new schizophrenia drug temporarily named

Allon Therapeutics Inc. (TSX: NPC) announced today that its lead neuroprotective drug candidate, davunetide, has been granted Fast Track

May 7, 2012

Allon Therapeutics, Inc San Diego, corporate profile and product articles.

The Allon Therapeutics Inc. (NPCUF) Competitors by Product report shows Allon Therapeutics Inc. products and services according to the actual sector or line of

Allon Therapeutics - Annual Sales, industry, address, phone, website, company overview, executives, and employee information listed in Spoke''s business

Allon Therapeutics Inc. ©2010 Allon Therapeutics Inc. 1. Allon Therapeutics Inc. Corporate Overview. ASENT Annual Meeting. February 2010

May 21, 2012

Get detailed financial information on Allon Therapeutics Inc. (TSE:NPC) including real-time stock quotes, historical charts & financial news, all for free!

12, 2011) - Allon Therapeutics Inc. (TSX:NPC) today provided an update on progress in its pivotal clinical trial in progressive supranuclear

Allon Therapeutics Inc. company profile,Allon Therapeutics Inc. Address:506- 1168 Hamilton St. VancouverBC V6B 2S2 Canada,Website:,Contact Person:

Latest Allon Therapeutics Share Price and News. A Canadian biotechnology company developing drugs that protect against neurodegenerative conditions such

November 2, 2011

Browse a daily summary of experts opinions on stocks and stock investment information.

ㆍCompany, Allon Therapeutics Inc. ㆍCountry, Canada. ㆍSpecialty, Neurodegenerative disease (Alzheimer's disease, schizophrenia)

Allon Therapeutics Inc. Therapeutic Competitor Report contains detailed information on pipelines by phase and therapeutic indication as well as management

Gauge financial strength for ALLON THERAPEUTICS INC (NPC) by looking at snapshots of assets and liabilities through time. Detailed Balance Sheets with

February 2, 2012

VANCOUVER, BRITISH COLUMBIA, Nov 08, 2011 (MARKETWIRE via COMTEX) -- Allon Therapeutics Inc. /quotes/zigman/31763 CA:NPC

VANCOUVER, BRITISH COLUMBIA-- - Allon Therapeutics Inc. , today announced that its shareholders have approved the investment by Neuro Discovery II

VANCOUVER, British Columbia -- Allon Therapeutics Inc. (TSX:NPC), The Neuro Protection Company(TM), announced today the publication of

Allon Therapeutics. NPC; TSX; Other Services. Latest 0.27; CurrencyC$; Change --; Percent Change --; Volume --; Jan 9, 2012 1:47:30 PM TSX data delayed 15

March 3, 2012

Leadership | Allon Therapeutics Inc. Executive Team: Gordon C. McCauley President & Chief Executive Officer. Gordon McCauley was appointed President of

Allon Therapeutics Provides Pivotal Study Update and Q2 Operating Results Aug 12, 2011. from Marketwire · Allon Therapeutics Provides Pivotal Study Update

Allon Therapeutics, the Vancouver, BC-based developer of drugs for neurological disorders, said today it has raised $10 million from a limited

Vantage Clips Featuring Allon Therapeutics. VantageClips Featuring Allon Therapeutics 1:01. VantageClips; Délka: 1:01; Zobrazení: 40; Štítky: vantagewire

March 3, 2012

VANCOUVER, April 24, 2007— Allon Therapeutics Inc. (TSX: NPC), The Neuro Protection CompanyTM, today released new data confirming

virsitil's photostream (99) · Logo Seaside Family Services; Identity Silver Dynamics; Logo Allon Therapeutics; Identity ShirtMagic; Identity Solid

Allon Therapeutics Inc.: Pilot Clinical Trial Initiated to Evaluate Davunetide in Tau -Pathology Dementias from Market Wire.

News on Allon Therapeutics (Ticker: NPC) continually updated from thousands of sources around the net.

March 15, 2012

Allon Therapeutics, Inc. Interview Questions by Position. There are currently no Allon Therapeutics, Inc. interview questions by position. Submit one. Interviews

Allon Therapeutics Inc. - Product Pipeline Review - H2 2011 Summary Global Market Direct's pharmaceuticals report,

Allon Therapeutics. Vantage Clips Featuring Allon Therapeutics. Tags: News vantagewire Allon Therapeutics Allon Healthcare Pharma health Vantage Clips

View the basic NPC.TO stock chart on Yahoo! Finance. Change the date range, chart type and compare ALLON THERAPEUTICS INC. against other companies.

April 9, 2012

Get FREE realtime stock quotes on all Canadian and American exchanges. Vantage Wire is offering free stock quotes, realtime TSX, TSX-V,

Dr. J. Steven Whitaker M. D. J. D, Allon Therapeutics, Inc., Vancouver, BC - Business Contact Information in Jigsaw's business directory. Jigsaw's business

Xconomy Allon Treads Into the Great Unknown, Alzheimer's Disease, With New Kind of Drug. Vancouver, BC, May 18, 2011--Allon

Allon Therapeutics' presentation will be available 24/7 for 90 days. Investors may download shareholder materials from the "virtual trade booth"

April 4, 2012

Allon Therapeutics Inc. - Product Pipeline Review - H2 2011 : Market Research Report Allon Therapeutics Inc. - Product Pipeline Review - H2

Allon Therapeutics Ltd. NPC. Categories: Biotech. Share |. Printer-friendly version. Recent Shoutbox. Get your voice heard and Make a Post! There is no activity.

Allon Therapeutics Releases First Quarter 2011 Operating Results Allon Therapeutics Inc. (TSX:NPC) today announced its unaudited

Allon Therapeutics Inc. ("Allon Therapeutics" or the "Company") (TSX:NPC) announced today that, further to its press release dated September

April 27, 2012

Stock List. ALLON THERAPEUTICS INC. (NPC). Listing Exchange: TSX. Quote: All data delayed 15 minutes. Bid Size, Bid Price, Ask Price, Ask Size, Last Price

Pharmacy Choice | (Datamonitor via COMTEX) Allon Therapeutics Inc., a biotechnology company, has initiated a pivotal Phase II/III clinical trial

This page contains information about Allon Therapeutics Inc.(NPC)

Allon Therapeutics. News · Allon, Genta programs win FDA fast-track status. Fierce Biotech. Allon Therapeutics · davunetide · fast track · FDA · Genta · Tesetaxel

December 22, 2011

Allon Therapeutics Inc. ©2011 Allon Introduction to Allon Therapeutics. ∎ What we do? Allon Therapeutics founded in 2001. ∎ Public


Name:

Email:

Phone:

Info:

Copyright © 2010-2012 dietpillsbeauty.com